Forget Humira -- Here's What You Need to Know About AbbVie

Yes, the times they are a-changin' for Humira. The drug now faces stiff biosimilar competition in Europe. And, yes, AbbVie's (NYSE: ABBV) overall performance still hinges largely on Humira. But none of this is news for anyone who has followed the big drugmaker.